213686-00-1Relevant academic research and scientific papers
BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6
-
Paragraph 00244, (2018/12/13)
The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2 and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
Asymmetric synthesis of (2R,5R)-2,5-diaminohexan-1,6-dioic acid
Bull, Steven D.,Chernega, Alexander N.,Davies, Stephen G.,Moss, William O.,Parkin, Richard M.
, p. 10379 - 10388 (2007/10/03)
Schollkopf's auxiliary 16 was added to bis-lactim iodide 21 to give 1,2- bis[(3S,6R)-3,6-dihydro-2,5-dimethoxy-3-isopropylpyrazin-6-yl]ethane 22 in 50% d.e. Dimer 22 was separated from its diastereoisomer 23 and deprotected using 6M HCl to afford homochiral (2R,5R)-2,5-diaminohexan-1,6-dioic acid 24.
